Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

2.5K
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
2.5K
Peptic Ulcer01:27

Peptic Ulcer

50
Peptic ulcers are erosive lesions of the gastric or duodenal lining, most commonly caused by Helicobacter pylori infection. This Gram-negative, helical bacterium has adapted to survive the stomach’s acidic environment by producing urease, which converts urea into ammonia and carbon dioxide. The ammonia neutralizes gastric acid in the bacterium’s immediate environment, allowing colonization of the gastric mucosa. H. pylori attaches to mucus-secreting epithelial cells, penetrates the...
50
Gastritis II: Pathophysiology01:26

Gastritis II: Pathophysiology

87
The pathophysiology of gastritis begins with the colonization of the stomach lining by Helicobacter pylori (H. pylori). This bacterium spreads mainly via the oral-oral route through saliva or shared utensils, and can also be transmitted in overcrowded or unhygienic environments through contaminated water, despite its brief survival outside the body.ColonizationOnce ingested, H. pylori enters the stomach and begins colonization by navigating through the mucus layer lining the stomach wall. It...
87
Peptic Ulcer Disease II: Pathophysiology01:24

Peptic Ulcer Disease II: Pathophysiology

76
Peptic ulcer disease develops when protective mechanisms of the gastrointestinal mucosa are overwhelmed by harmful factors, leading to localized erosions in the stomach or proximal duodenum. The main causes are Helicobacter pylori infection and chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs).Helicobacter pylori–Induced InjuryBacterial Adaptation and Colonization:H. pylori is a spiral, Gram-negative bacterium adapted to the acidic stomach. and transmitted through oral-oral or...
76
Peptic Ulcer Disease II: Pathophysiology01:28

Peptic Ulcer Disease II: Pathophysiology

3.0K
Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
3.0K
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

815
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
815

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Early axonal injury in fentanyl intoxication.

Acta neuropathologica communications·2026
Same author

The Somatic Mosaicism across Human Tissues Network.

Nature·2025
Same author

Updated joint ESPGHAN/NASPGHAN guidelines for management of Helicobacter pylori infection in children and adolescents (2023).

Journal of pediatric gastroenterology and nutrition·2024
Same author

Loss of TDP-43 splicing repression occurs early in the aging population and is associated with Alzheimer's disease neuropathologic changes and cognitive decline.

Acta neuropathologica·2023
Same author

The TNF-Alpha Inducing Protein is Associated With Gastric Inflammation and Hyperplasia in a Murine Model of <i>Helicobacter pylori</i> Infection.

Frontiers in pharmacology·2022
Same author

WITHDRAWN: SARS-CoV-2 invades cognitive centers of the brain and induces Alzheimer's-like neuropathology.

bioRxiv : the preprint server for biology·2022

Related Experiment Video

Updated: May 5, 2026

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance
05:23

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance

Published on: March 7, 2025

895

Vaccinating against Helicobacter pylori in the developing world.

Shamila Zawahir1, Steven J Czinn1, John G Nedrud2

  • 1Department of Pediatrics; University of Maryland School of Medicine; Baltimore, MD USA.

Gut Microbes
|November 21, 2013
PubMed
Summary

Developing a Helicobacter pylori vaccine faces challenges due to host immune suppression. Future vaccines must overcome these regulatory mechanisms for improved efficacy against H. pylori infection.

Keywords:
Helicobacter pyloridyspepsiagastric cancervaccine

More Related Videos

One-step Negative Chromatographic Purification of Helicobacter pylori Neutrophil-activating Protein Overexpressed in Escherichia coli in Batch Mode
10:44

One-step Negative Chromatographic Purification of Helicobacter pylori Neutrophil-activating Protein Overexpressed in Escherichia coli in Batch Mode

Published on: June 18, 2016

9.1K
Rapid Detection of Fecal Antigen of Helicobacter pylori Infection Based on Double Antibody Sandwich Detection Technology
03:33

Rapid Detection of Fecal Antigen of Helicobacter pylori Infection Based on Double Antibody Sandwich Detection Technology

Published on: May 23, 2025

1.2K

Related Experiment Videos

Last Updated: May 5, 2026

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance
05:23

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance

Published on: March 7, 2025

895
One-step Negative Chromatographic Purification of Helicobacter pylori Neutrophil-activating Protein Overexpressed in Escherichia coli in Batch Mode
10:44

One-step Negative Chromatographic Purification of Helicobacter pylori Neutrophil-activating Protein Overexpressed in Escherichia coli in Batch Mode

Published on: June 18, 2016

9.1K
Rapid Detection of Fecal Antigen of Helicobacter pylori Infection Based on Double Antibody Sandwich Detection Technology
03:33

Rapid Detection of Fecal Antigen of Helicobacter pylori Infection Based on Double Antibody Sandwich Detection Technology

Published on: May 23, 2025

1.2K

Area of Science:

  • Microbiology
  • Immunology
  • Vaccinology

Background:

  • Helicobacter pylori infection affects over half the global population, with incidence exceeding 90% in developing nations.
  • H. pylori-associated diseases like ulcers and gastric cancer disproportionately impact developing regions.
  • Despite extensive research in mouse models, translating vaccine development successes to human clinical trials for H. pylori has been limited.

Purpose of the Study:

  • To investigate the reasons behind the limited success of Helicobacter pylori vaccine candidates in clinical trials.
  • To understand the host immune response to H. pylori infection and its implications for vaccine efficacy.
  • To identify strategies for improving Helicobacter pylori vaccine effectiveness.

Main Methods:

  • Review of in vivo and in vitro studies analyzing host responses to H. pylori infection in mice and humans.
  • Analysis of immune responses activated during H. pylori infection.
  • Evaluation of factors influencing vaccine efficacy in preclinical and clinical settings.

Main Results:

  • Mouse models have shown promise for H. pylori vaccine development, testing various antigens, immunization routes, doses, and adjuvants.
  • Clinical trials have shown limited success in reducing bacterial load, despite activating immune responses.
  • Host responses to H. pylori infection involve immunoregulatory mechanisms that suppress anti-H. pylori immunity.

Conclusions:

  • Improved Helicobacter pylori vaccine efficacy requires strategies to overcome or reprogram host-induced immune suppression.
  • Understanding and targeting these immunoregulatory mechanisms is crucial for successful H. pylori vaccine development.
  • Future vaccine approaches should consider factors that modulate the host's immune response to H. pylori.